

Stacey L Martiniano, Mscs

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6722467/publications.pdf>

Version: 2024-02-01

33
papers

1,001
citations

567281

15
h-index

434195

31
g-index

36
all docs

36
docs citations

36
times ranked

1120
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical characteristics of people with cystic fibrosis and frequent fungal infection. <i>Pediatric Pulmonology</i> , 2022, 57, 152-161.	2.0	8
2	Host and pathogen response to bacteriophage engineered against <i>Mycobacterium abscessus</i> lung infection. <i>Cell</i> , 2022, 185, 1860-1874.e12.	28.9	93
3	Newborn Screening for Cystic Fibrosis: A Qualitative Study of Successes and Challenges from Universal Screening in the United States. <i>International Journal of Neonatal Screening</i> , 2022, 8, 38.	3.2	7
4	Clinical characteristics and outcomes associated with <i>Inquilinus</i> infection in cystic fibrosis. <i>Journal of Cystic Fibrosis</i> , 2021, 20, 310-315.	0.7	6
5	Population Genomics of <i>Mycobacterium abscessus</i> from U.S. Cystic Fibrosis Care Centers. <i>Annals of the American Thoracic Society</i> , 2021, 18, 1960-1969.	3.2	42
6	Detection of bacterial pathogens using home oropharyngeal swab collection in children with cystic fibrosis. <i>Pediatric Pulmonology</i> , 2021, 56, 2043-2047.	2.0	12
7	Comment on Munck et al., Feb, 2021. <i>Journal of Cystic Fibrosis</i> , 2021, 20, 717-718.	0.7	2
8	Improving outcomes for Colorado's IRT-IRT-DNA cystic fibrosis newborn screening algorithm by implementing floating cutoffs. <i>Molecular Genetics and Metabolism</i> , 2021, 134, 65-67.	1.1	11
9	Pharmacokinetics of oral antimycobacterials and dosing guidance for <i>Mycobacterium avium</i> complex treatment in cystic fibrosis. <i>Journal of Cystic Fibrosis</i> , 2021, 20, 772-778.	0.7	6
10	ATS Core Curriculum 2021. <i>Pediatric Pulmonary Medicine: Pulmonary Infections</i> . <i>ATS Scholar</i> , 2021, 2, 452-467.	1.3	1
11	Outcomes of infants born during the first 9 years of CF newborn screening in the United States: A retrospective Cystic Fibrosis Foundation Patient Registry cohort study. <i>Pediatric Pulmonology</i> , 2021, 56, 3758-3767.	2.0	15
12	Safety and effectiveness of a risk-stratified venous thromboembolism prophylaxis algorithm in young people with cystic fibrosis. <i>Thrombosis Research</i> , 2021, 206, 36-41.	1.7	3
13	Population Genomics and Inference of <i>Mycobacterium avium</i> Complex Clusters in Cystic Fibrosis Care Centers, United States. <i>Emerging Infectious Diseases</i> , 2021, 27, 2836-2846.	4.3	19
14	Challenging scenarios in nontuberculous mycobacterial infection in cystic fibrosis. <i>Pediatric Pulmonology</i> , 2020, 55, 521-525.	2.0	8
15	Highlights from the 2019 North American Cystic Fibrosis Conference. <i>Pediatric Pulmonology</i> , 2020, 55, 2225-2232.	2.0	2
16	Urine lipoarabinomannan as a marker for low-risk of NTM infection in the CF airway. <i>Journal of Cystic Fibrosis</i> , 2020, 19, 801-807.	0.7	14
17	Nontuberculosis Mycobacterial Disease. , 2019, , 498-506.e4.		0
18	Antimicrobial susceptibility testing (AST) and associated clinical outcomes in individuals with cystic fibrosis: A systematic review. <i>Journal of Cystic Fibrosis</i> , 2019, 18, 236-243.	0.7	84

#	ARTICLE	IF	CITATIONS
19	Reconciling Antimicrobial Susceptibility Testing and Clinical Response in Antimicrobial Treatment of Chronic Cystic Fibrosis Lung Infections. <i>Clinical Infectious Diseases</i> , 2019, 69, 1812-1816.	5.8	62
20	Prevention of transmission of <i>Mycobacterium abscessus</i> among patients with cystic fibrosis. <i>Current Opinion in Pulmonary Medicine</i> , 2019, 25, 646-653.	2.6	18
21	Nontuberculous Mycobacterial Infections in Cystic Fibrosis. <i>Thoracic Surgery Clinics</i> , 2019, 29, 95-108.	1.0	55
22	Highlights from the 2017 North American Cystic Fibrosis Conference. <i>Pediatric Pulmonology</i> , 2018, 53, 979-986.	2.0	7
23	Safety and Effectiveness of Clofazimine for Primary and Refractory Nontuberculous Mycobacterial Infection. <i>Chest</i> , 2017, 152, 800-809.	0.8	115
24	Venous thromboembolism in children with cystic fibrosis: Retrospective incidence and intrapopulation risk factors. <i>Thrombosis Research</i> , 2017, 158, 161-166.	1.7	11
25	Nontuberculous mycobacteria in cystic fibrosis: Updates and the path forward. <i>Pediatric Pulmonology</i> , 2017, 52, S29-S36.	2.0	42
26	Cystic fibrosis. <i>Current Opinion in Pediatrics</i> , 2016, 28, 312-317.	2.0	44
27	Nontuberculous mycobacterial infections in cystic fibrosis. <i>Current Opinion in Pulmonary Medicine</i> , 2016, 22, 629-636.	2.6	8
28	Nontuberculous Mycobacterial Infections in Cystic Fibrosis. <i>Clinics in Chest Medicine</i> , 2016, 37, 83-96.	2.1	65
29	Venous Thromboembolism in Pediatric Cystic Fibrosis. <i>Blood</i> , 2016, 128, 3808-3808.	1.4	1
30	Nontuberculous Mycobacterial Infections in Cystic Fibrosis. <i>Clinics in Chest Medicine</i> , 2015, 36, 101-115.	2.1	71
31	Clinical Significance of a First Positive Nontuberculous Mycobacteria Culture in Cystic Fibrosis. <i>Annals of the American Thoracic Society</i> , 2014, 11, 36-44.	3.2	102
32	Advances in the Diagnosis and Treatment of Cystic Fibrosis. <i>Advances in Pediatrics</i> , 2014, 61, 225-243.	1.4	13
33	<i>Mycobacterium abscessus</i> Induces a Limited Pattern of Neutrophil Activation That Promotes Pathogen Survival. <i>PLoS ONE</i> , 2013, 8, e57402.	2.5	52